INMB vs. ABOS, ZURA, KOD, OPT, IPHA, ADVM, CGEN, ELEV, IPSC, and XFOR
Should you be buying INmune Bio stock or one of its competitors? The main competitors of INmune Bio include Acumen Pharmaceuticals (ABOS), Zura Bio (ZURA), Kodiak Sciences (KOD), Opthea (OPT), Innate Pharma (IPHA), Adverum Biotechnologies (ADVM), Compugen (CGEN), Elevation Oncology (ELEV), Century Therapeutics (IPSC), and X4 Pharmaceuticals (XFOR). These companies are all part of the "biological products, except diagnostic" industry.
Acumen Pharmaceuticals (NASDAQ:ABOS) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation, dividends and community ranking.
Acumen Pharmaceuticals presently has a consensus target price of $12.25, indicating a potential upside of 264.58%. INmune Bio has a consensus target price of $16.00, indicating a potential upside of 59.68%. Given INmune Bio's higher possible upside, equities research analysts plainly believe Acumen Pharmaceuticals is more favorable than INmune Bio.
71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.7% of INmune Bio shares are owned by institutional investors. 7.5% of Acumen Pharmaceuticals shares are owned by company insiders. Comparatively, 36.1% of INmune Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Acumen Pharmaceuticals has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500. Comparatively, INmune Bio has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500.
INmune Bio received 119 more outperform votes than Acumen Pharmaceuticals when rated by MarketBeat users. Likewise, 75.69% of users gave INmune Bio an outperform vote while only 64.29% of users gave Acumen Pharmaceuticals an outperform vote.
Acumen Pharmaceuticals has a net margin of 0.00% compared to Acumen Pharmaceuticals' net margin of -26,333.59%. INmune Bio's return on equity of -23.40% beat Acumen Pharmaceuticals' return on equity.
In the previous week, INmune Bio had 1 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 9 mentions for INmune Bio and 8 mentions for Acumen Pharmaceuticals. INmune Bio's average media sentiment score of 0.76 beat Acumen Pharmaceuticals' score of 0.10 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media.
INmune Bio has higher revenue and earnings than Acumen Pharmaceuticals. INmune Bio is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Acumen Pharmaceuticals beats INmune Bio on 9 of the 16 factors compared between the two stocks.
Get INmune Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
INmune Bio Competitors List
Related Companies and Tools
